Dubai Final-v20.indd - World Allergy Organization
Dubai Final-v20.indd - World Allergy Organization
Dubai Final-v20.indd - World Allergy Organization
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
EXHiBitOr DirECtOrY<br />
lg life Sciences, ltd Booth 14<br />
20 lg twin towers<br />
Yoido-Dong<br />
Youngdungpo-gu<br />
seoul 150-721<br />
south Korea<br />
Phone: +82 2 3773 7296<br />
Fax: +82 2 3773 7329<br />
Website: www.lgls.com<br />
in a bid to find the next-generation diagnostic methodologies, lgls<br />
is developing seminal technology and products related to automated<br />
allergy system for screening, DnA analysis and lab-on-a-chip<br />
technology, which can be used to simultaneously find multiple<br />
disease markers in a short time. We will continue our efforts to<br />
emerge as a top global brand in the diagnostic field.<br />
<strong>Allergy</strong> screening Products<br />
test items intended Use<br />
Alloscreen screening of 42 kinds of specific allergen<br />
Alloscan 2.0 strip scanner for Alloscreen kit<br />
Allostation s Fully automated allergy system for screening<br />
for Alloscreen kit<br />
mEaaaiC - middle East asia allergy, asthma<br />
and immunology Congress Booth 22<br />
middle East Asia <strong>Allergy</strong> Asthma immunology Congress (mEAAAiC) is<br />
a regional congress that presents a valuable and unique<br />
opportunity for both specialists and general physicians, to update<br />
their knowledge and advance their skills. mEAAAiC generally<br />
attracts key opinion leaders from the region as well as world<br />
renowned international faculty. the 1st mEAAAiC in march 2009 was<br />
held in collaboration with international organizations like the WAO,<br />
EAACi, AAAAi and ACAAi. the congress attracted around 1,500<br />
participants from over 43 countries. With the resounding success<br />
in 2009, mEAAAiC is now an established biennial congress with the<br />
next edition to be held in April 2011. For more information, please<br />
visit www.meaaaic.org<br />
merck Booth 12<br />
1 merck Drive<br />
Whitehouse station, nJ 08889-3497<br />
UsA<br />
Phone: (908) 423-1000<br />
Website: www.msd.com<br />
today’s msD is a global healthcare leader working to help the world<br />
be well. msD is a tradename of merck & Co., inc., with headquarters<br />
in Whitehouse station, n.J., U.s.A. through our prescription<br />
medicines, vaccines, biologic therapies, and consumer care and<br />
animal health products, we work with customers and operate in<br />
more than 140 countries to deliver innovative health solutions. We<br />
also demonstrate our commitment to increasing access to healthcare<br />
through far-reaching policies, programs and partnerships. msD. Be<br />
well. For more information, visit www.msd.com.<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
novartis Booth 10<br />
novartis international Ag<br />
CH-4002 Basel<br />
switzerland<br />
Phone: +41 61 324 11 11<br />
Fax: +41 61 324 80 01<br />
Website: www.novartis.com<br />
At novartis Booth, there will be a display of videos discussing:<br />
• the quality of life of patients living with severe allergic asthma<br />
• the impact Xolair has on changing the way patients live with<br />
severe allergic asthma<br />
• the mode of action of Xolair<br />
As well, novartis will distribute at the booth some booklets about real<br />
adults case studies treated with Xolair.<br />
to insure that visiting physicians get all the inquiries answered, at<br />
the booth we’ll have product specialists that can answer physician<br />
questions or record their queries in order to answer them at a later<br />
time.<br />
All this aside from other promotional activities that abide by the<br />
Pharma Code of Conduct.<br />
nycomed Booth 17<br />
<strong>Dubai</strong> Healthcare City<br />
PO Box 1586<br />
<strong>Dubai</strong><br />
UAE<br />
Phone: +0097 1438 34207<br />
Fax: +0097 1435 72839<br />
Website: www.nycomed.com<br />
Email: sheriff.hassan@nycomed.ae<br />
Alvesco:<br />
o Has a novel mechanism of action for exceptional balance of safety<br />
and efficacy.<br />
o Efficacy comparable with the leading iCs.<br />
o safety and tolerability comparable with placebo.<br />
o Once-daily dosing helps to improve compliance.<br />
Alvesco is:<br />
lUng tArgEtED<br />
• smaller particle size for greater lung deposition and less oral<br />
exposure.<br />
• greater than 50% of the inhaled dose is delivered directly to the<br />
lung.<br />
lUng ACtiVAtED<br />
• Converted to its active form by esterases in the lung.<br />
• lipid conjugation for prolonged anti-inflammatory effects and<br />
once-daily dosing.<br />
lUng limitED<br />
• High protein binding for systemic safety.<br />
• Only 1% is available for systemic exposure.<br />
• Quickly metabolized in the liver for first-pass inactivation.<br />
www.worldallergy.org 25<br />
FinAl PrOgrAm
Change language